pain
Lyrica to be made class C drug in Northern Ireland
April 1, 2019Sales and Marketing Lyrica, Northern Ireland, class c, illegal drugs, pain, pregabalin
Pregabalin – sold under the brand name Lyrica – will now be treated as a class C drug in Northern …
Sacklers accused of personally directing deceptive OxyContin sales tactics
January 17, 2019Sales and Marketing OxyContin, Purdue Pharma, opidois, opioid crisis, pain, sackler
Members of the billionaire Sackler dynasty personally directed efforts to mislead doctors and patients as to the dangers of the …
Mylan launches generic of Valeant’s Ultram in the US
March 29, 2016Manufacturing and Production, Sales and Marketing FDA, Mylan, Valeant, abbreviate new drug application, generic, pain, tramadol, ultram
Mylan (NASDAQ, TASE: MYL) has announced the launch of its generic version of Valeant’s Ultram tablets in the US. The …
FDA lifts ban on Pfizer Lilly pain study
March 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Pfizer, lilly, pain, tanezumab
Pfizer and Eli Lilly will resume Phase III clinical trials of tanezumab following the FDA lifting a ban on trials …
Blow for Pfizer as Lyrica misses target
March 13, 2015Sales and Marketing FDA, Lyrica, Pfizer, fibromyalgia, pain, pregablin
A late-stage study of Pfizer’s Lyrica has failed to demonstrate it has any significant pain reduction in patients with fibromyalgia. …
New Lyrica formulation effective in trials
December 19, 2014Sales and Marketing HIV, Lyrica, Pfizer, pain, pregabalin, shingles
Pfizer has reported positive Phase III results for a new formulation of its painkiller Lyrica. In the study, a controlled-release …
ProStrakan pays £230m for Archimedes
July 14, 2014Sales and Marketing Archimedes, Cancer, ProStrakan, pain, pecfent
The ProStrakan Group is to looking to expand its offerings via a payment of £230 million for Archimedes Pharma. The …
Lyrica fails in diabetes and HIV pain
May 9, 2012Sales and Marketing Lyrica, Pfizer, neuropathic pain, pain
Two separate Phase III trials of Lyrica have failed to show benefits in treating nerve pain – one in HIV …
